CHANGES IN SERUM COMPLEMENT ACTIVITY DURING ANTI-CD20 AND ANTI-CD52 MONOCLONAL ANTIBODY THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Stasilojc Grzegorz; Felberg Anna; Taszner Michal; Urban Aleksandra; Ma Shuo; Blom Anna; Lundin Jeanette; Osterborg Anders; Okroj Marcin

首页> 外文期刊>Molecular Immunology >CHANGES IN SERUM COMPLEMENT ACTIVITY DURING ANTI-CD20 AND ANTI-CD52 MONOCLONAL ANTIBODY THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

【24h】

CHANGES IN SERUM COMPLEMENT ACTIVITY DURING ANTI-CD20 AND ANTI-CD52 MONOCLONAL ANTIBODY THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

机译：慢性淋巴细胞白血病患者抗CD20和抗CD52单克隆抗体治疗期间血清补体活性的变化（CLL）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Molecular Immunology》 |2019年第2019期|共1页
作者
Stasilojc Grzegorz; Felberg Anna; Taszner Michal; Urban Aleksandra; Ma Shuo; Blom Anna; Lundin Jeanette; Osterborg Anders; Okroj Marcin;
展开▼
作者单位

Univ Gdansk Intercoll Fac Biotechnol Dept Med Biotechnol Gdansk Poland;

Univ Gdansk Intercoll Fac Biotechnol Dept Med Biotechnol Gdansk Poland;

Med Univ Gdansk Dept Hematol &

Transplantol Gdansk Poland;

Univ Gdansk Intercoll Fac Biotechnol Dept Med Biotechnol Gdansk Poland;

Northwestern Univ Feinberg Sch Med Chicago IL 60611 USA;

Lund Univ Dept Translat Med Malmo Sweden;

Karolinska Univ Hosp Solna Dept Hematol Stockholm Sweden;

Karolinska Univ Hosp Solna Dept Hematol Stockholm Sweden;

Univ Gdansk Intercoll Fac Biotechnol Dept Med Biotechnol Gdansk Poland;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医学免疫学;
关键词

相似文献

外文文献
中文文献
专利

1. CHANGES IN SERUM COMPLEMENT ACTIVITY DURING ANTI-CD20 AND ANTI-CD52 MONOCLONAL ANTIBODY THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) [J] . Stasilojc Grzegorz, Felberg Anna, Taszner Michal, Molecular Immunology . 2019,第期

机译：慢性淋巴细胞白血病患者抗CD20和抗CD52单克隆抗体治疗期间血清补体活性的变化（CLL）
2. P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients [J] . S Eketorp Sylvan, J Lundin, M Ipek, Journal for ImmunoTherapy of Cancer . 2014,第S2期

机译：P27。 Alemtuzumab（抗CD52单克隆抗体）作为复发/难治性慢性淋巴细胞白血病（CLL）患者的单药治疗–连续患者的单区域经验
3. Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells. [J] . Smolewski P, Duechler M, Linke A, Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis . 2006,第12期

机译：硼替佐米联合抗CD20或抗CD52单克隆抗体对慢性淋巴细胞白血病细胞的加性细胞毒作用。
4. Chronic Lymphocytic Leukemia (CLL): New Insight on the Pathogenesis of CLL Cell Survival [C] . L. Lagneaux, A. Delforge, M. Dejeneffe, European Haematology Association . 2002

机译：慢性淋巴细胞白血病（CLL）：对CLL细胞生存发病机制的新见解
5. Kinase Targeting Therapies in Chronic Lymphocytic Leukemia: Mechanisms of Acquired Ibrutinib Resistance and the Pre-Clinical Development of OSU-T315. [D] . Liu, Ta-Ming. 2014

机译：激酶靶向疗法在慢性淋巴细胞性白血病中：获得性依鲁替尼耐药性的机制和OSU-T315的临床前开发。
6. P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients [O] . S Eketorp Sylvan, J Lundin, M Ipek, 2014

机译：P27。 Alemtuzumab（抗CD52单克隆抗体）作为复发/难治性慢性淋巴细胞白血病（CLL）患者的单药治疗–连续患者的单区域经验
7. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). [O] . Lundin J, Kimby E, Björkholm M, 2002

机译：皮下抗CD52单克隆抗体alemtuzumab（Campath-1H）作为B细胞慢性淋巴细胞性白血病（B-CLL）患者的一线治疗的II期试验。

CHANGES IN SERUM COMPLEMENT ACTIVITY DURING ANTI-CD20 AND ANTI-CD52 MONOCLONAL ANTIBODY THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

著录项

引文网络

相似文献

相关主题

期刊订阅